Malignancies in systemic lupus erythematosus

Abstract

Purpose of Review Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared to the general population. This review summarizes the recent literature on risk of malignancy in SLE and proposed mechanisms for these altered susceptibilities. Recent Findings Recent studies have confirmed previous data showing an increased risk of non-Hodgkin’s lymphoma, lung, liver, vulvar/vaginal, and thyroid malignancies, while demonstrating a decreased risk of breast and prostate cancer. Lymphomagenesis in SLE has been linked to increased activity of multiple inflammatory cytokines as well as possible viral etiologies. The decreased rates of hormone-sensitive cancers such as breast and prostate is speculated to be related to the presence of lupus autoantibodies and down-regulation of certain proteins in SLE. This knowledge has been utilized to investigate new therapeutic modalities for these malignancies. Summary Recent data confirm previously reported altered malignancy rates in SLE. Most striking in recent years are publications further elucidating mechanisms underlying cancer development in SLE, and subsequent investigations of potential therapeutics modulating these pathways.

Analysis of the miRNA–mRNA networks in malignant transformation BEAS-2B cells induced by alpha-particles

“…Cell adhesion molecules (CAMs) are closely related to cell invasion and metastasis (Jassam et al, 2015). Systemic lupus erythematosus displayed an increased risk for development of overall malignancies (Goobie et al, 2015;Mao et al, 2015b). In the present study, MAPK and cytokine-cytokine receptor interaction, CAM, and systemic lupus erythematous were activated while the ribosome and TGF-β signaling pathways were inhibited in the malignant transformation cell.…”

Persistent Afebrile Abdominal Pain: An Unusual Case of Segmental Colitis in an Immunocompromised Host

“…Among SLE patients in particular, increased expression of cytokine pathways, the proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) may explain the pathogenic B-cell activation and offer a common link between autoimmunity and lymphoma [10]. …”

Late-onset systemic lupus erythematosus in the elderly

“…Отмечаются увеличение ри-ска развития неходжкинской лимфомы, рака легких, пече-ни, шейки матки и щитовидной железы и снижение часто-ты рака молочной железы и простаты по сравнению с ана-логичными показателями в популяции. Высказывается предположение, что лимфопролиферативные заболевания обусловлены повышенной активностью провоспалитель-ных цитокинов и, возможно, сопутствующей вирусной ин-фекцией (вирус Эпштейна-Барр), цитотоксической тера-пией (особенно экспозицией циклофосфамида), тогда как снижение частоты гормонально-зависимых опухолей (мо-лочной и предстательной желез) связано с наличием аутоан-тител и снижением выработки некоторых белков при СКВ (например, heat shock protein 27, HSP-27) [35][36][37][38]. Однако убедительных данных эпидемиологических исследований об ассоциации СКВ со злокачественными новообразовани-ями, в том числе в зависимости от возраста дебюта и прово-димой терапии, не получено.…”